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Background and purpose: Haemorrhagic stroke is associ-
ated with substantial mortality and disability, thus preven-
tion and appropriate treatment of acute intracerebral haem-
orrhage is crucial. We aimed to evaluate the use and the
early and late outcomes impact of drugs administered
before and in acute haemorrhagic stroke in a real-world
practice.
Material and methods: Haemorrhagic stroke patients hospi-
talized between 1st March 2007 and 29th February 2008 and
reported in Polish Hospital Stroke Registry were analysed.
Fully anonymous data were collected with standardized,
authorized access, web-based questionnaire. Multivariate
regression models were used to adjust for case-mix and eval-
uate the impact of drugs used prior to or in acute haemor-
rhagic stroke on outcomes. The early outcomes were defined
as in-hospital mortality or poor outcome (death or depen-
dency – modified Rankin Scale ≥ 3) at hospital discharge,
while late outcomes covered one-year survival.
Pharmacotherapy prior to and in acute haemorrhagic stroke. 
The use of pharmacotherapy and drugs-associated outcomes in real-world practice
– findings from the Polish Hospital Stroke Registry
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St reszc zen ie
Wstêp i cel pracy: Udar krwotoczny jest zwi¹zany ze znaczn¹
œmiertelnoœci¹ oraz niepe³nosprawnoœci¹ chorych; wymaga
zarówno skutecznej profilaktyki, jak i leczenia ostrej fazy.
Celem badania by³a ocena farmakoterapii stosowanej przed
zachorowaniem i w ostrej fazie udaru krwotocznego mózgu,
w warunkach codziennej praktyki klinicznej. 
Materia³ i metody: Analizie poddano grupê chorych hospi-
talizowanych z powodu udaru krwotocznego mózgu od
1.03.2007 r. do 29.02.2008 r., zg³oszonych do Szpitalnego
Rejestru Udarów Mózgu w Polsce. W pe³ni anonimowe dane
gromadzono z wykorzystaniem strukturyzowanego kwestio-
nariusza internetowego z autoryzowanym dostêpem. Do oce-
ny wp³ywu leków stosowanych przed zachorowaniem oraz
w ostrej fazie udaru krwotocznego na rokowanie wykorzy-
stano wieloczynnikow¹ analizê regresji z uwzglêdnieniem
wp³ywu innych czynników rokowniczych. Wczesne wyniki
leczenia zdefiniowano jako œmiertelnoœæ wewn¹trzszpitaln¹ 
i niekorzystny efekt terapeutyczny (punktacja ≥ 3 w zmody-
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Introduction
Haemorhagic stroke, also named intracerebral haem-
orrhage (ICH), accounts for 10-15% of strokes, which
translates into approximately 2 million new episodes 
of ICH worldwide each year [1]. It is associated with
a 30-day mortality rate that approaches 50%, and only
20% of survivors are functionally independent at 
6 months [2]. Haemorrhagic stroke is associated with
a recurrence rate of 1-3% per year. Approximately half
of the stroke recurrences after haemorrhagic stroke are
in the form of another intracranial bleeding, with the
other half corresponding to ischaemic stroke. Despite
its substantial frequency and its major toll in terms of
acute mortality and long-term disability, haemorrhagic
stroke has been relatively understudied, especially with
regard to treatment and the value of various measures
for secondary prevention.
Haemorrhagic strokes are most often due to high
blood pressure. Adequate control of blood pressure
could prevent the majority of haemorrhagic strokes as
untreated or poorly controlled hypertension increases
the risk of intracranial haemorrhage by three to four-
fold. Another risk factor is diabetes, although it slight-
ly increases the risk of haemorrhagic stroke including
intracranial bleeding following thrombolysis in acute
ischaemic stroke. Certainly, excessive alcohol consump-
tion increases the risk of haemorrhagic stroke and light
to moderate intake was not showed beneficial contrary
to ischaemic stroke. Smoking and possibly migraine with
aura are also another risk factors [3].
Oral anticoagulants are associated with mean annual
rate of haemorrhagic stroke of 0.2% and either more
severe stroke or worse prognosis. Anticoagulation resump-
tion after intracranial haemorrhage is a challenge. Cur-
rent guidelines for patients with a comparatively lower
risk of cerebral infarction (eg. atrial fibrillation [AF] with-
out prior ischaemic stroke) and a higher risk of amyloid
angiopathy (eg. elderly patients with lobar bleeding) or
with very poor overall neurological function recommend
consideration of an antiplatelet agent for prevention of
ischaemic stroke. While in patients with a very high risk
of thromboembolism it may be reasonable to restart war-
farin therapy at 7 to 10 days after onset of the haemor-
rhagic stroke [4]. Antiplatelets for prevention of is -
chaemic events after ICH are considered safe in general,
but caution should be paid to patients with lobar bleed-
ing suspected to be due to cerebral amyloid angiopathy.
Statins are effective for prevention of ischaemic events but
they seem to increase the risk of lobar ICH recurrence.
Medical therapy of acute haemorrhagic stroke is
mainly focused on adjunctive measures to minimize
fikowanej skali Rankina) przy wypisie ze szpitala, natomiast
odleg³e wyniki leczenia jako ca³kowit¹ œmiertelnoœæ w ci¹gu
pierwszego roku od udaru.
Wyniki: Analizie poddano dane 3111 osób hospitalizowanych
z powodu udaru krwotocznego (œrednia wieku: 68,9 roku;
kobiety: 46,7%). Analiza farmakoterapii wykaza³a ma³y odse-
tek chorych z nadciœnieniem têtniczym stosuj¹cych leki hipo-
tensyjne przed udarem i wzglêdnie czêste wykorzystanie
w leczeniu ostrego udaru krwotocznego antybiotyków oraz
leków wazoaktywnych i neuroprotekcyjnych. W modelach
wieloczynnikowych potwierdzono niekorzystny wp³yw na
rokowanie leków przeciwzakrzepowych, ale nie przeciw -
p³ytkowych, i obserwowano przeciwstawny efekt statyn sto-
sowanych przed udarem i w trakcie hospitalizacji.
Wnioski: Zbyt rzadkie wykorzystanie leków hipotensyjnych
w kontroli nadciœnienia têtniczego w okresie poprzedzaj¹cym
hospitalizacjê istotnie wp³ywa na ryzyko udaru krwotocznego.
Czêste stosowanie antybiotyków oraz leków wazoaktywnych
i neuroprotekcyjnych wskazuje na potrzebê dalszej poprawy
jakoœci opieki w ostrym udarze krwotocznym.
S³owa kluczowe: udar krwotoczny, farmakoterapia, leki hipo-
tensyjne, leki przeciwzakrzepowe, statyny.
Results: A total of 3111 haemorrhagic stroke patients (mean
age: 68.9 years; females: 46.7%) was reported. The analysis
of pharmacotherapy showed low preventive use of hypoten-
sive agents in hypertensive patients, high consumption of
antibiotics and still overuse of vasoactive or neuroprotective
compounds in acute haemorrhagic stroke. Regression mod-
els confirmed expected negative impact on stroke outcomes
associated with oral anticoagulants but not antiplatelets and
inconsistent impact of statins used prior to or in acute haem-
orrhagic stroke.
Conclusions: Preventive underuse of hypotensive compounds
contribute substantially to haemorrhagic stroke risk. The high
consumption of antibiotics and neuroprotective or vasoactive
compounds in haemorrhagic acute stroke reflect the need to
improved quality and evidence-based clinical practice.
Key words: haemorrhagic stroke, pharmacotherapy, antihyper -
tensives, oral anticoagulants, statins.
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haematoma enlargement as specific causal treatment is
not available. Symptomatic treatment is primarily fo -
cused on high blood pressure control, prevention of
thromboembolism in high-risk patients and surgical
treatment for selected individuals.
We aimed to evaluate the use and the early and late
outcomes impact of drugs administered before and in
acute haemorrhagic stroke patients reported in the Pol-
ish Hospital Stroke Registry and hospitalized in 2007
and 2008.
Material and methods
Data on hospitalized stroke patients reported with-
in third edition of the Polish Hospital Stroke Registry
covering time-frame from 1st March 2007 to 29th Feb-
ruary 2008 were analysed. All neurological centres in
Poland were invited to participate and voluntarily report
fully anonymous stroke patients data. Stroke was defined
according to WHO definition as a neurological deficit
of cerebrovascular cause that persists beyond 24 hours
or is interrupted by death within 24 hours. Haemor-
rhagic stroke were identified based on ICD-10 classifi-
cation (I61).
Data were collected with standardized web-based
questionnaire, specially designed to eliminate misre-
porting and based on Swedish Stroke Registry and
WHO STEPwise approach to Surveillance. The access
to Registry was dedicated to each participating centre
and protected from unauthorised use. Data were report-
ed fully anonymously and, additionally, analysed with
blinded information on patients allocation to particular
stroke centre. To ensure the quality of reported data, ran-
domly selected centres were audited. The following
information was reported for all patients: demograph-
ics (age, gender), cardiovascular risk factors, modified
Rankin Scale (mRS) prior to stroke, time of symptom
onset (if unknown, the time patient was last seen with-
out symptoms), clinical status at admission (level of con-
sciousness), hospital management, stroke outcomes
(mRS at discharge) and drugs used before stroke, dur-
ing hospital stay and prescribed on discharge. The man-
ual including all important terms and definitions and
easily accessible on the official website of the Registry
was provided. The history of cerebrovascular events was
defined as documented hospitalisation due to confirmed
stroke or transient ischaemic attack (TIA). Hyperten-
sion was reported for patients diagnosed before or dur-
ing index hospitalization (by repeated blood pressure
measurements after acute phase, i.e. first seven days);
threshold values for hypertension were based on JNC
VII report (systolic blood pressure > 140 mm Hg or
> 130 mm Hg for diabetic or chronic renal failure
patients; diastolic blood pressure > 90 mm Hg or 
> 80 mm Hg for diabetics or chronic renal failure
patients) [5]. Atrial fibrillation encompassed paroxys-
mal, persistent and permanent arrhythmias. Ischaemic
heart disease could have been only reported for patients
objectively diagnosed with either interventional or non-
interventional methods. The history of myocardial in -
farction was defined as acute coronary syndrome treat-
ed in hospital 30 days before stroke onset. Finally,
dyslipidaemias could have been reported only if labora-
tory tests conducted 3 months preceding stroke onset 
or during first 24 hours were available for the follow-
ing: total cholesterol (> 200 mg%) or LDL cholesterol
(> 100 mg%) or triglycerides (> 150 mg%) or HDL
cholesterol (< 40 mg% for males and < 50 mg% for
females). The following drug groups were distinguished:
aspirin, other antiplatelets, recombinant tissue plasmi -
nogen activator, blood pressure lowering agents, oral
anticoagulants, heparins, insulins, oral antidiabetic
drugs, vasoactive (i.e. nicergoline, vinpocetine) and neu-
roprotective (i.e. piracetam) agents, statins, antibiotics.
In the third edition of the Polish Hospital Stroke Reg-
istry, unique Polish Resident Identification Number
(PESEL) was used to track annual survival of stroke
patients based on data collected by Department of
National Central Evidences run by Ministry of Inter-
nal Affairs and Administration. 
Statistical analysis
Data were analysed separately for haemorrhagic
stroke following ICD-10 classification (I61). Calcula-
tions and estimations were conducted for the whole
haemorrhagic stroke patients population and appropri-
ate subgroups identified, i.e. target population for stud-
ied drugs. Data were presented as numbers and corre-
sponding percentages.
Multivariate regression models were used to adjust
for case-mix and evaluate the impact of drugs used pri-
or to or in acute haemorrhagic stroke on outcomes. The
early outcomes were defined as in-hospital mortality or
poor outcome (death or dependency – mRS ≥ 3) at hos-
pital discharge. The late outcomes covered one-year fol-
low-up and the number of days from stroke onset to
death for fatal cases. Logistic regression models and Cox
proportional hazard model were applied for early and
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late outcomes, respectively. Dedicated models controlled
for age, sex, cardiovascular risk factors, disability assess -
ed with mRS prior to stroke, consciousness at admis-
sion and treatment centres.
Results
A total number of 123 stroke centres reported data on
3111 haemorrhagic stroke patients in the third edition of
the Polish Hospital Stroke Registry. On average, every
ninth stroke patient was diagnosed with primary ICH.
Mean age of patients was 68.9 years (95% confi-
dence interval [CI]: 68.4-69.3). For patients with first-
ever stroke, mean age was 68.4 (95% CI: 67.9-68.9).
Females represented 46.7% of the registered population.
Baseline characteristics, including cardiovascular risk
factors, is presented in the Table 1. Hypertension was
most prevalent cardiovascular risk factor, followed by
ischaemic heart disease and diabetes. Less than half of
patients presented were alert on admission to hospital.
Consciousness disturbances were probably related to
prompt medical healthcare seeking as reflected by high
percentage of patients admitted within 6 hours from
symptom onset.
The detailed analysis of pharmacotherapy used in
patients prior to and in acute haemorrhagic stroke pa -
tients for general patients population and subgroups is
showed in the Table 2.
Regression models results are presented in Table 3.
After adjusting for case-mix we could confirm some
N %
History of stroke 442 14.2
Hypertension 2296 73.8
Atrial fibrillation 357 11.5
Ischaemic heart disease 556 17.9
History of myocardial infarction 138 4.4
Diabetes 447 14.4
Smoking 367 11.8
Alcohol abuse 329 10.6
Dyslipidaemias 420 13.5
Modified Rankin scale prior to stroke
0 1810 64.4
1 344 12.2
2 216 7.7
3 139 4.5
4 123 4.4
5 179 6.4
Time from onset to admission < 6 h 1494 48.0
(including missing data or unknown 
time of onset)
Consciousness disturbances:
Alert 1404 45.1
Drowsy 748 24.1
Stupor 352 11.3
Coma 606 19.5
Table 1. Baseline characteristics of haemorrhagic stroke patients reported in
third edition of the Polish Hospital Stroke Registry
Drugs used prior to stroke N %
Blood pressure lowering agents  1449 63.1
in hypertensive patients
Blood pressure lowering agents  302 68.3
in patient with history of stroke
Antiplatelets in patients with history of stroke 112 25.3
Antiplatelets in patients with history of MI 158 26.4
or IHD
Anticoagulants in patients with AF 75 21.0
Statins 193 6.2
Statins in patients with history of stroke 34 14.5
Statins in patients with history of MI 93 15.6
or IHD
Statins in patients with dyslipidaemias 86 20.5
Vasoactive agents 76 2.4
Neuroprotective agents 114 3.7
Antibiotics 33 1.1
Drugs used during hospital stay N %
Blood pressure lowering agents 2448 78.7
Blood pressure lowering agents 2044 89.0
in hypertensive patients
Heparins 54 6.4
Statins 535 17.2
Insulins in diabetic patients 239 53.5
Antibiotics 1404 45.1
Vasoactive agents 284 9.1
Neuroprotective agents 732 23.5
Table 2. Pharmacotherapy prior to stroke and used during hospital stay
MI – myocardial infarction, IHD – ischaemic heart disease, AF – atrial fibrillation
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expected harm resulting from oral anticoagulants use
prior to stroke, which was associated with worse early
and late survival (in-hospital death: odds ratio [OR] =
= 2.83 [95% CI: 1.60-5.02]; one year mortality: 
OR = 1.84 [95% CI: 1.39-2.44]), but not disability
assessed at discharge from hospital. The outcomes asso-
ciated with statins were inconsistent as these drug used
prior to haemorrhagic stroke were observed to increase
mortality while administered during hospital stay were
of complete opposite effect.
Discussion
Alike for ischaemic stroke, drug utilisation before
cerebrovascular accident and in acute haemorrhagic
stroke is important in monitoring of the current medical
practice. It can also point out pharmacotherapy potential
benefit or harm in real-world settings as reported for
ischaemic stroke patients [6]. Data from the Polish Hos-
pital Stroke Registry provide a unique opportunity both
to evaluate the current practice and to provide evidence
on possible drug related benefit in haemorrhagic stroke
based on everyday clinical practice data.
The pharmacotherapy practice prior to and in acute
haemorrhagic stroke
As hypertension stands for the most important haem-
orrhagic stroke risk factor, the use of antihypertensive
drugs is essential in either primary or secondary pre-
vention. In the INTERSTROKE study, hypertension
(defined as blood pressure > 160/90 mm Hg) was more
often observed in haemorrhagic then ischaemic stroke
patients (83 and 66%, respectively) and authors con-
cluded that almost three quarters of haemorrhagic stroke
risk is attributable to high blood pressure [7]. In the
Polish Hospital Stroke Registry, antihypertensive drugs
were used prior to haemorrhagic stroke on average by
two out of three patients with hypertension and sub-
stantially less commonly compared to 75% of patients
with ischaemic stroke [6]. We lack data on effectiveness
of blood pressure control with antihypertensive prior to
stroke in the Polish Hospital Stroke Registry. How ever,
it should be stressed that analysis of all three editions of
the Polish Hospital Stroke Registry (i.e. 2001-2002,
2004-2005 and 2007-2008 years) showed some nega-
tive trends of decreased use of hypotensive agents in
haemorrhagic stroke patients with hypertension (com-
pared to first 2001-2002 edition, 15% fewer patients
with hypertension in 2007-2008 were treated with blood
pressure lowering compounds before haemorrhagic
stroke onset; data not presented) and that needs further
monitoring. 
Majority of hypertensive patients were treated with
blood pressure lowering compounds during hospitaliza-
tion. As blood pressure tends to fluctuate in acute stroke
and blood pressure lowering agents are not recom-
mended below 180/105 mm Hg, the assessment of anti-
hypertensive agents is limited. Although the hyperten-
sion contributes more to the risk of haemorrhagic then
ischaemic stroke, the use of blood pressure lowering
agents was very similar – three out of four stroke patients
were prescribed blood pressure lowering drugs and that
rate increased to 90% for individuals with hypertension.
Guidelines recommend that all ischaemic and haemor-
rhagic stroke patients regardless of blood pressure value
should be offered antihypertensive drugs. As the sec-
ondary stroke prevention should be established during
hospital stay and hardly ever hypotensive treatment needs
late start (i.e. after discharge), one can argue there is still
Drugs associated with in-hospital mortality: p-value OR 95% CI
Oral anticoagulants prior to stroke < 0.001 2.832 1.603-5.017
Statins prior to stroke 0.001 2.128 1.335-3.384
Statins in hospital < 0.001 0.292 0.207-0.406
Antibiotics in hospital 0.001 1.674 1.354-2.074
Drugs associated with functional outcome at discharge:
Antibiotics in hospital < 0.001 3.599 3.331-3.891
Drugs associated with one-year survival:
Oral anticoagulants prior to stroke < 0.001 1.841 1.390-2.436
Table 3. The statistically significant findings of multivariate regression modelling on the drugs associated with early and late haemorrhagic stroke outcome
OR – odds ratio, CI – confidence interval
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room to improve secondary prevention with blood pres-
sure lowering agents also in haemorrhagic stroke.
Oral anticoagulants are associated with risk of bleed-
ing, including severe intracranial episodes. During
1990s the incidence of anticoagulant-associated ICH
quintupled in United States and the majority of this
change was attributed to increased warfarin use [8]. In
our study, 21% of AF patients prior to haemorrhagic
stroke were reported oral anticoagulants users (twice
more often than AF patients hospitalized with ischaemic
stroke) [6]. The corresponding values in other studies
were similar and ranged from 18.3 to 23.4% [9,10].
Antiplatelets before haemorrhagic stroke onset were
used only by quarter of patients with history of myocar-
dial infarction or ischaemic heart disease and slightly more
often in patients with secondary stroke. Moreover the
antiplatelets were generally twice less often used for haem-
orrhagic stroke patients with history of cardiovascular dis-
ease compared with ischaemic stroke patients [6].
Statins were used only for 15% of patients with his-
tory of stroke or myocardial infarction and ischaemic
heart disease. Alike antiplatelets, that is generally also
twice less often compared with ischaemic stroke patients
with history of cardiovascular event [6]. Use of statin
was more driven by dyslipidaemia then cardiovascular
diseases and did not reflect clinical guidelines. 
Insulins were more often used in haemorrhagic than
ischaemic stroke patients [6]. That can result from more
severe stroke and the need to monitor glycaemia with
insulin rather oral hypoglycaemic agents.
Antibiotics usage reflects the risk of infectious com-
plications and indirectly also indicates the quality of acute
stroke care. Almost half of haemorrhagic stroke patients
in the Polish Hospital Stroke Registry were treated with
antibiotics in hospital and that is high compared with
results of the systematic review of 87 studies involving
137 817 patients, which estimated the overall pooled infec-
tion rate complicating acute stroke at 30% or 45% for all
trials or intensive care unit studies, respectively [11].
Finally, the vasoactive (i.e. nicergoline, vinpocetine)
and neuroprotective (i.e. piracetam) compounds, which
have not been shown effective in randomised controlled
trials, are still often used in Polish haemorrhagic stroke
patients but less often compared to ischaemic stroke [6].
Although alike for ischaemic stroke, these drugs are less
and less popular in following edition of the Polish Hos-
pital Stroke Registry (data not presented; in first 2001-
2002 edition of the Registry the corresponding rates
were 16.3 and 56.3% for vasoactive and neuroprotec-
tive drugs, respectively), they are still fairly common. As
a kind of negative indicator, the use of vasoactive and
neuroprotective agents can reflect the dissemination of
evidence-based clinical practice in either haemorrhagic
and ischaemic stroke. It should be stressed that these
drugs alike for ischaemic stroke were used rarely prior
to haemorrhagic stroke and much more often during
hospital stay, thus hospital management resulted in
increased use of these drugs and therefore should be fur-
ther monitored and improved.
The impact of drugs used before cerebrovascular
accident or in acute haemorrhagic stroke on patients
prognosis
Unlike ischaemic stroke, blood pressure lowering
drugs used either prior to or during acute haemorrhag-
ic stroke did not affect the outcome of haemorrhagic
stroke patients and this is new finding as hardly ever
studied. 
The harmful impact of oral anticoagulants used pri-
or to hemorrhagic stroke on short and long-term mor-
tality observed in our study confirmed other findings.
The increased odds of early death and long term mor-
tality associated with pretreatment with oral anticoagu-
lants ranged from 1.5 to 3.2 [9,10,12,13]. In the study
by Stead et al., reversal of increased INR to normal with
either fresh frozen plasma, vitamin K, activated factor
VIIa or platelets did not influence mortality or functional
outcome. Probably warfarin’s effect on ICH mortality
is mediated by increased risk of in-hospital haematoma
expansion as warfarin did not increase ICH volume at
admission [14].
We observed no impact of pretreatment with anti -
platelets on prognosis in haemorrhagic stroke, most
probably because of  low doses of aspirin used regular-
ly in cardiovascular prevention in Poland. Relevant pub-
lications are inconclusive. Some studies, especially those
reporting high mean dose of aspirin used, found in -
creased risk of early mortality of haemorrhagic stroke
patients [13,15-18]. Another studies, including analy-
sis of randomized trials, did not find any harmful impact
of antiplatelets used prior to haemorrhagic stroke [19,
20]. Finally, systematic review of 25 studies (including
15 unpublished trials) also showed inconsistent results
[21]. Antiplatelets in uni- and multivariate analysis were
associated with increased mortality, but not poor func-
tional outcome. 
Unlike to ischaemic stroke, statins used prior to
haemorrhagic stroke were associated with higher in-hos-
pital mortality in our study. Only a few studies have
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addressed the pretreatment with statins and haemor-
rhagic stroke outcomes. Most of the publications showed
no relation between statins used prior to stroke and mor-
tality or functional outcome [22-24]. Other, more re -
cent, studies showed even some benefit produced by pre-
treatment with statins in haemorrhagic stroke, thus our
study findings should be interpreted with caution and
do not support the avoiding of statins due to intracra-
nial bleeding risk [25-28]. Statins used during hospi-
tal treatment were associated with opposite outcomes
compared with statins used prior to stroke. The data on
statins benefits in haemorrhagic stroke are lacking. In
SPARCL (Stroke Prevention by Aggressive Reduction in
Cholesterol Levels) study, atorvastatin used in non-car-
dioembolic stroke patients reduced the risk of recurrent
stroke and TIA but increased slightly the risk of
intracranial bleeding, although increased fatalities were
not observed [29,30]. Patients more likely to suffer
intracranial bleeding while treated with statins in sec-
ondary prevention were males, with history of intracra-
nial bleeding and concomitant hypertension.
Our study has a number of limitations, some of them
were already mentioned [6]. Main limitation is volun-
tarily reported, not fully representative, sample of reg-
istered patients and limited scope of collected data. Nev-
ertheless, it is so far the largest study on real world
everyday stroke care in Poland.
Conclusions 
The preventive use of blood pressure lowering agents
in haemorrhagic stroke is inadequate and needs to be
monitored and improved. Underuse of hypotensive
compounds contribute substantially to haemorrhagic
stroke risk. The benefits of statins in haemorrhagic
stroke is less evident compared to ischaemic stroke. 
The high consumption of antibiotics and neuroprotec-
tive or vasoactive compounds in heamorhagic acute
stroke reflect the need to improved quality and evidence
based clinical practice. 
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